RULING ON FDA/LAERDAL INJUNCTION DISPUTE EXPECTED BY END OF APRIL
This article was originally published in The Gray Sheet
Executive Summary
RULING ON FDA/LAERDAL INJUNCTION DISPUTE EXPECTED BY END OF APRIL at the earliest from Judge Helen Frye at the U.S. District Court in Portland, Oregon. The court heard oral arguments in mid- February on the case, in which Laerdal is contesting agency efforts to enjoin the company from production and distribution of external defibrillators. Memoranda of fact and law based on the February hearing are due March 29, with responses to be completed by April 12.
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.